Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
135 hedge funds and large institutions have $893M invested in Alder Biopharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 50 increasing their positions, 40 reducing their positions, and 26 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
25% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 40
18% more capital invested
Capital invested by funds: $756M → $893M (+$137M)
8% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 26
4% less funds holding
Funds holding: 140 → 135 (-5)
93% less call options, than puts
Call options by funds: $1.06M | Put options by funds: $16M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$36.1M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$19.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15.4M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$13.6M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$30.5M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$24.2M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$16.5M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8M |
| 5 |
AC
Ascend Capital
Orinda,
California
|
-$7.72M |
ALDR Hedge Fund Activity: Q1 2018 in Review
135 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q1 2018, worth a combined $893M — up 18% from $756M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ALDR and 24 opened new positions — a net loss of 2 holders — while 40 trimmed existing stakes and 50 added.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $36.1M. The largest seller was Citadel Advisors, cutting an estimated $30.5M.
- 135 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q1 2018, down from 140 in Q4 2017.
- Funds reported $893M of Alder Biopharmaceuticals stock for Q1 2018, up 18% quarter-over-quarter.
- 24 funds opened new Alder Biopharmaceuticals positions in Q1 2018 and 26 closed out, a net change of -2 holders.
- The largest Alder Biopharmaceuticals buyer in Q1 2018 was PFM Health Sciences, an estimated $36.1M added.
- The largest Alder Biopharmaceuticals seller in Q1 2018 was Citadel Advisors, an estimated $30.5M sold.
Based on aggregated 13F filings for Q1 2018.